What drugs do hypertension patients take in clinical practice? Structure of antihypertensive drugs in a large siberian region

Objective. To assess the frequency of prescribing of different groups of antihypertensive drugs (AHD) in the treatment of patients with arterial hypertension (AH) among patients of the Krasnoyarsk territory according to the Russian epidemiological studies ESSE-RF.

Materials and methods. 1,603 persons aged 25–64 years, selected through systematic stratified multistage randomization among the population attached to the four outpatient clinics of Krasnoyarsk and Berezovsky district hospital were studied. All included subjects were subjected to a detailed survey of office blood pressure measurements. Results. The proportion of those on monotherapy was 53.4%. The most commonly accepted AHD, including in the combination therapy, were angiotensin-converting enzyme inhibitors (ACEI) – in 51% of cases, beta-blockers – 28.9 percent, angiotensin receptor blockers (ARBS) – 25,2%, diuretics – 23,2%, calcium channel blockers (CCB) – 11.9%, central action drugs – 2.0% and alpha-blockers – 0.4 percent. Beta-blockers often were taken by those of younger age – 38.1 per cent, mainly men aged 25–34 years (50.0 per cent). Among the combinations of AHD the most frequently encountered combination was ACEI + diuretic (6,8%), followed by rthe frequency of prescription by ARBS + diuretic, beta-blocker + diuretics, ARBS + CCB, ACE-I + CCB.

Conclusion. The frequent prescription of ACE inhibitors and insignificant use of central action is noted. The high level of violence of use of AHD monotherapy in patients with hypertension (53,4%) is alarming, which may be one of the reason for the relatively low efficiency of antihypertensive therapy (31.6 percent). Beta-blockers were indicated unreasonably often for young men with hypertension aged 25–34 years. 

1. Jarari N, Rao N, Peela JL, Ellafi KA, Shakila S, Said AR et al. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens, 2016, 22: 7.

2. Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии. Клинические рекомендации. Кардиологический вестник, 2015;1: 3-30.

3. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8), Supplemental Content. JAMA, 2014, 311: 507-520.

4. Mancia G, Fagard R, Narkiewicz K, Redan J, Zanchetti A, Bohm M et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens, 2013, 31(10): 1925-38.

5. Жернакова Ю.В., Чазова И.Е. Роль β-адрено-блокаторов в лечении артериальной гипертонии: что мы знаем сегодня. Системные гипертензии, 2015, 1: 10-18.

6. Girerd X, Hanon O, Pannier B, Vaisse B, Mourad JJ. Trends in the use of antihypertensive drugs in France from 2002 to 2012: FLAHS surveys. Ann Cardiol Angeiol (Paris), 2013, 62(3): 210-214.

7. Xu H, He Y, Xu L, Yan X, Dai H. Trends and patterns of five antihypertensive drug classes between 2007 and 2012 in China using hospital prescription data. Int J Clin Pharmacol Ther, 2015, 53(6): 430-437.

8. Sarganas G, Knopf H, Grams D, Neuhauser HK. Trends in antihypertensive medication use and blood pressure control among adults with hypertension in Germany. Am J Hypertens, 2016, 29(1): 104-113.

9. Леонова М.В., Белоусова Ю.Б., Штейнберг Л.Л., Алимова Э.Э., Смирнова Е.П., Белоусова Д.Ю. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии ПИФАГОР IV (опрос пациентов с артериальной гипертонией). Кардиология, 2015, 12(3): 11-18.

10. Бойцов С.А., Баланова Ю.А., Шальнова С.А., Деев А.Д., Артамонова Г.В., Гатагонова Е.М. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика, 2014, 14(4): 4-14.

11. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open, 2013, 3(8): e003423.

12. Yoon SS, Carrol MD, Fryar CD. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS Data Brief, 2015, 220: 1-8.

13. Van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, Boersma E. Angiotensinconverting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J, 2012, 33(16): 2088-2099.